Podcasts about T1

In this episode of Summoning Insight, Thorin and Yamato dive deep into the League of Legends competitive scene, discussing key topics from Worlds playoffs scheduling to player transfers, roster stability, and format debates. They explore the pros and cons of condensed playoff schedules for teams like T1, the single-elimination vs. double-elimination tournament formats, and the market predictions for high-profile roster moves such as Inspired's potential signing with FlyQuest before free agency.  Visit https://www.Kalshi.com and use promo code LFN. Make your first $100 worth of trades and you'll automatically receive a $10 bonus!  Black Friday is around the corner, and Raycon audio products are up to 30% off sitewide! Go to https://buyraycon.com/LFNOPEN to save on Raycon audio products sitewide.  Upgrade your wallet today! Get 10% off Ridge at https://Ridge.com by using code SI at checkout  Eat smart with Factor! Go to https://FactorMeals.com/lfn50off and use code lfn50off to get 50% off your first box, plus Free Breakfast for 1 Year.  Ready to say yes to saying no? Make the switch at https://MINT MOBILE.com/summoning.Upfront payment of $45 required (equivalent to $15/mo.). Limited time new customer offer for first 3 months only.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this live SocialNext Toronto 2025 conversation, guest host Maddie Alvarez sits down with Nithya Ramachandran, President and CSO at T1, a full-stack sponsorship and experience agency. Together, they unpack why modern sponsorships are more than logo slaps and check-writing, they're strategic growth levers built on trust, collaboration, and meaningful activation.Nithya breaks down how brands can use partnerships to reach audiences in ways media alone can't, why asking “why” is a marketer's most powerful tool, and how the best campaigns are built on shared values, not just shared budgets.If you've ever wondered how to make sponsorships actually work (and prove their ROI), this conversation is a masterclass in modern partnership marketing.

Timestamps0:00 Intro 0:38 So you want to be a KT fan 1:15 2013 KT 11:59 2014 KT 16:05 2015 KT 25:56 2016-2018 KT 34:54 2019-2022 KT 36:50 2023 KT 41:42 2025 KT why now 55:21 T1 vs. KT expectations 1:03:05 T1 vs. KT full circle moment

Esportmaníacos 2413: En el programa de hoy hemos charlado del futuro de Fnatic y de Razork de cara a 2026 ya que los rumores no dejan claro que el jungla español pueda salir del conjunto naranja. También hemos charlado de Worlds, la final T1 vs KT y los récords del propio Faker. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:17:45 - El pick de Mundo vs AL 00:24:00 - Calendario de Worlds 00:44:00 - SKT Faker vs T1 Faker 01:09:00 - El futuro de Razork y FNC y full offseason 01:51:20 - El roster de SK

FAKER. EIGHT. WORLD. FINALS.At this point, what more can you even say? The Unkillable Demon King has done it again — carrying T1 back to the Worlds Finals for an unbelievable eighth time. His plays were unreal, his reads were perfect, and his legacy just keeps getting stronger. You can never, ever count Faker out.Plus… is Quid really joining Team Liquid? The Dive crew reacts to the rumors and what it could mean for the LCS heading into next year.Timestamps:0:00 - Intro & Team Liquid Roster Rumors9:12 - Worlds Condensed Format16:38 - Semifinals: KT vs GEN40:44 - Semifinals: T1 vs TES50:06  - Nami's Usefulness in Pro-Play55:35 - The Game from T1's Point of View1:13:25 - The T1 System1:17:43 - Predictions for Finals

Timestamps0:00 Intro 2:50 T1 adapts better than anyone 8:43 Game breakdowns 15:38 Keria is GOAT support 17:27 Current T1 vs. Old T1 19:01 Faker stat dump 21:56 Faker is killing the LPL

The League of Legends Betting Podcast  Sunday, November 2nd, 2025 - Worlds 2025 Semifinals Day Two Recorded on: Saturday, November 1st at 7:25pm Eastern   Intro/Recap (0:26) T1 vs TOP Esports (30:22)   You can find more, exclusive content to go along with this show on My Patreon. My Twitter/X is @GelatiLOL P&L Sheet for 2025 can be found here and pinned to the top of my Twitter.

Timestamps0:00 Intro2:45 Favorites at Worlds7:13 How dominant was GenG actually12:27 KT vs. DRX15:50 BDD vs. Chovy21:25 Where it went wrong for GenG game by game31:47 Drafts35:57 TES vs. T1 tomorrow

Minu seekordseks vestluskaaslaseks on T1 keskuse tegevjuht Tarmo Hõbe. Tema karjäär sai hoo sisse, kui ta aastaid tagasi Sportlandis turundusjuhina tööle asus. Sellest ajast peale on teda kandnud üks ja sama joon – teda ei tõmba stabiilsed ja turvalised ärid. Tarmo päris kirg on kaoses korra loomine: olukorrad, kus teised näevad ummikuid, näeb tema hoopis potentsiaali. Nii on ta ellu äratanud Unibet Arena (endise Saku Suurhalli), toonud Eestisse WRC sarja etapi ja tõmmanud mudast välja T1 keskuse. Tarmoga räägime tema mõtteviisist – miks teda tõmbavad just rasked ja ebamäärased olukorrad ning miks ta usub, et tõeline motivatsioon tekib siis, kui selge tulevikuvisioon ja eesmärk on silme ees.

Timestamps0:00 Intro2:55 T1 stats11:10 AL retrospective12:58 Game by game breakdown15:44 Game 217:09 Game 318:20 Game 420:07 Game 525:11 GenG is the favorites now27:20 TES upset potential28:33 This format is great

Esportmaníacos 2409: En el programa de hoy hemos hecho un repaso de lo que hasta ahora ha sido LA serie del Mundial: T1 contra Anyone's Legends, los pandas. Posteriormente vimos un poco qué es lo que nos espera mañana y pasado en las semifinales de Worlds y al final, hablamos sobre la polémica de BLG en un karaoke y la respueta de Tencent a esto. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:16:30 - Caps renovado en G2 oficialmente 00:21:33 - Primer mapa T1 vs AL 00:32:27 - Segundo mapa T1 vs AL 00:48:35 - Tercer mapa T1 vs AL 01:05:10 - Cuarto mapa T1 vs AL 01:17:10 - Quinto mapa T1 vs AL 01:38:00 - Se acaba el mundial de los pandas (como os quejéis de spoiler aquí os pego ban eh) 01:46:00 - Las semifinales de Worlds 01:54:00 - BLG, Karaoke pétalos y Tencent

The League of Legends Betting Podcast  Friday, October 31st, 2025 - Worlds 2025 Quarterfinals Day Four Recorded on: Thursday, October 30th at 645am Eastern   Intro/Recap (0:26) Anyone's Legend vs T1 (10:12)   You can find more, exclusive content to go along with this show on My Patreon. My Twitter/X is @GelatiLOL P&L Sheet for 2025 can be found here and pinned to the top of my Twitter.

NA is officially OUT of Worlds — and the Dive crew is here to unpack everything that went down in the last days of Swiss Stage. From the wild drafts to broken champs, Kobe, Azael, and Meteos will be breaking down every major storyline heading into Quarterfinals. Is Neeko actually busted? Can G2 take down TES? Can T1 defend their title? Tune in to find out!Worlds returns on Tuesday, October 28th and at 12:00am PT (midnight) where HLE takes on Gen.G.Timestamps:0:00 - Intro1:32 - NA out of Worlds8:31 - Stakes/expectations/reality at Worlds16:31 - What are these drafts?20:20 - Neeko is broken27:06 - Gen.G vs Worlds37:02 - Quarterfinal Champion/Gameplay Breakdown43:07 - Deeper look at KT vs CFO53:48 - G2 vs TES, an even match?1:06:38 - AL vs T1, can the underdog win?1:19:56 - Quarterfinal Predictions!

Según Juan Luis Álvarez, hay series que atentan contra la inteligencia. Se olfatea que son de mal gusto, se sabe que se han dejado arrollar por lo políticamente correcto o han tenido una primera temporada atroz... Por eso, como ejercicio de dignidad seriéfila, mejor pasar de ellas. Las Berrocal (Movistar +, T1, 4 episodios) No hay más que ver el trailer para entender que cuando la publicidad dice que Las Berrocal son mucho más que glamour, éxito y elegancia, no falta a la verdad... ni siquiera se acerca a ella. Este clan familiar cuenta, en el seriado, su día a día. Lo mejor: Parecen más soportables que otros clanes similares que tuvieron que pasar por esto para mantener su estatus de celebridad cutre y pagar la letra de la mansión. Lo peor: Que se tomen lo de la elegancia y el glamour en serio. Trailer Wonder Man (Disney +, T1, 8 episodios) Un nuevo héroe de Marvel salta a la palestra. El actor de Hollywood Simon Williams se sumerge en el mundo de los superhéroes a medida que obtiene sus propios poderes y se convierte en el nuevo superhéroe Wonder Man. Lo mejor: Lo del cambio de raza del personaje central parece que lo han llevado a cabo con cierto estilo. Lo peor: Cambiarle el color al personaje central, como peaje a lo políticamente correcto y a lo comercial, era innecesario teniendo en cuenta que ya hay un héroe de color de esas características. (Luke Cage) Trailer Respira (Netflix, 2 temporadas, 16 capítulos) Biel es uno de los residentes que lleva unos meses dejándose la piel en un hospital público. Cientos de guardias, miles de horas, que apenas le dejan tiempo para su vida, todo con tal de convertirse en el mejor doctor. Lo que no se imagina es que en el hospital va a estallar una huelga total, sin servicios mínimos. Los sanitarios se ven obligados a ello para tratar de concienciar a la población sobre su trabajo esencial y para protestar por todos los recortes intolerables que está sufriendo la sanidad pública. Lo mejor: La segunda temporada no puede ser peor que la primera. Lo peor: Es una copia barata de "Urgencias" con pretensión de estar muy al día. Trailer

Round 1 at the Bank of Utah Championship at Black Desert was suspended for darkness with 38 players on the course. This incomplete leaderboard is tightly packed with four at T1. Connor Howe and Zac Blair are low UPOTs at -3. Howe and David Liechty, both playing in their first PGA Tour event, join the pod. Sponsored by Goldenwest Credit Union. 

¡Vótame en los Premios iVoox 2025! Esportmaníacos 2403: En el programa de hoy hemos hablado largo y tendido de T1 y BLG, ya que ha sido un día muy extraño en el Mundial. También hemos visto el resultado del sorteo del último día del Suizo. Finalmente, hemos dado un pequeño repaso al mercato de LEC. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:11:00 - Hablamos del sorteo y del mental de T1 00:44:30 - Entra Irene a hablar de T1 es gratis 00:51:20 - T1 vs 100T Game 1 01:06:00 - T1 vs 100T Game 2 01:23:20 - Hablamos de BLG 01:32:50 - Mikyx se va de FNC 01:47:00 - Canna renueva con KC 01:55:40 - Vladi en negociaciones con cinco equipos

We are doing another LIVE show in NYC thanks to Red Bull! For tickets and more information head to: PlatChat.com

Hello and welcome back to another episode of The Dive, Driven by Kia! It's Worlds time!In this episode, Kobe joins the crew from China and we dive right into the wild opening match of Worlds — SKT vs IG, with TheShy putting on a show as always. We've also got the matchup everyone's been waiting for: FLY vs G2, (and Azael's already calling it). Plus, a preview of the next big matches and some spicy discussion on the meta — from Sion to Rek'Sai and everything in between.0:00 Intro3:22 T1 vs IG Series9:07 Sion is so OP15:27 Qiyana jungle seems strong22:16 Meteos' opinion on Rek'sai & the tank meta29:23 FlyQuest's performance and uncertainty44:20 NA vs EU rivalry58:15 Mid lane meta1:02:06 GEN vs TES preview1:07:58 HLE vs CFO preview1:15:14 BLG vs VKS preview1:18:57 MKOI vs TSW preview1:24:08 100T vs T1 preview

In this episode of The Everyday Ironman Podcast, Danny Buckley returns to share his unforgettable experience racing Ironman Wales—his first-ever Ironman-branded event! Based in the UK, Danny first joined the show in Episode 170 (August 2024), and this time he's back with stories of perseverance, jellyfish stings, and post-crash redemption. After wrecking his bike earlier in the year, Danny raced on his new Canyon Speedmax, completing the challenging course in under 12 hours despite a mid-marathon calf cramp. From a rainy pre-race day to clear skies on race morning, Danny describes the demanding 2-loop swim (including a sting from a Portuguese Man-o-war!) and the 1K run to T1 that had Mike pitching his famous Crocs-as-transition-shoes idea. Tune in for inspiration, laughs, and a real Age Group success story.Click here to be a podcast supporter. #EverydayIronman #IronmanWales #AgeGroupTriathlete #CanyonSpeedmax #TriathlonPodcast #SwimBikeRunFit, Healthy & Happy Podcast Welcome to the Fit, Healthy and Happy Podcast hosted by Josh and Kyle from Colossus...Listen on: Apple Podcasts SpotifySupport the show

Éternel adjoint à Malines, il a franchi cet été le pas vers le poste de T1, en succession de Besnik Hasi. La mue est réussie : au tiers du championnat, les Sang et Or luttent pour le haut de tableau. Au sortir de la trêve internationale, il évoque Paul Gascoigne, les vestiaires à 40°, le gouvernement Arizona, Benito Raman, son enfance molenbeekoise, René Vandereycken, les datas, David Hubert, les dérapages en bord de touche et Christian Burgess. Mais aussi Marc Coucke, le 4-2-3-1, Hein Vanhaezebrouck, le fameux 4e changement de Daniel Renders, le Football-Gate de 2018, le métro bruxellois, Benjamin Nicaise, la Play-Station chypriote et les trajets de Knokke. Et bien sûr… les klettes. Frederik Vanderbiest (coach Malines) passe « Sur Le Gril ».Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog You will learn: What holds up new treatments for diseases and conditions How long the FDA sits on a known safe medical medication before it is released to the public. Why safe and effective drugs are NOT approved by the FDA Why doctors are forced to use medications off label How you can help During my 44 years of medical practice, I have encountered conditions for which there is no approved medication or surgical treatment available as recognized by the American College of OBGYN or the FDA. This situation can present challenges both for physicians managing these patients and for individuals seeking relief from their symptoms. This issue is not often addressed on Dr Oz, in the news, or at medical conferences. For many conditions, physicians wait for the development of approved medications or treatments, and in the meantime may inform patients that there is currently no treatment or cure available. Some doctors may attribute a patient's concerns to aging, stating that it is a universal experience. While this may be accurate, such explanations may not provide comfort to patients seeking solutions to their symptoms. This lack of helpful guidance can discourage individuals from seeking medical care when they feel their concerns are not acknowledged. This seems to result from insurance companies prioritizing cost savings by minimizing patient care.  Every year insurance companies decrease what they pay doctors for their services, while their expenses go up, and the Government requires more and more work behind the scenes like HIPPA, OSHA, and Clia requirements that costs more to deliver the same service.  If you have a problem with the time your doctor spends with you then blame the insurance companies whose profits rise every year…Soon doctors will do what I do and only take cash.  The practice of medicine is not working in a free market. While insurance limits the prescriptions of medication to those meds that are FDA Approved, the FDA and medical specialty colleges often delay approval of new, low-risk treatments for up to 20 years after their effectiveness is demonstrated. This lengthy process should be reconsidered to treat people who are ill and suffering, now. There is plenty of research in the medical journals that explain the safety of new and effective treatments that can save peoples' lives that are not FDA approved yet. The FDA is not interested in expediting the release of medication/ devices quickly to those people who need help now. They drag out the testing of a medicine that has been effective for years and may or may not approve it. On the flip side they have approved many drugs that later are found to have severe side effects, and they just change the warnings on the medication inserts. They don't take them off the market except in severe cases. Drugs that have worked treating patients successfully are being used but are not FDA approved. These “grandfathered drugs” don't need to go through the testing that new drugs go through because they work with few well-known risks. I use many if these medications because they are inexpensive for my patients and are often more effective than new meds for the same problem. One of the drugs that the FDA has not had to approve is Armour Thyroid, a natural thyroid replacement. My experience with treatments not approved by the FDA Armour Thyroid: Armour Thyroid (AT) has been prescribed by doctors to replace thyroid hormones for about 100 years. It is natural, made from Pig thyroid. It only comes from “medical Pigs” that are raised for medical purposes.  We use medical pigs for skin grafts, and other parts of the pig to treat human diseases like heart valve replacements.  Armour Thyroid is composed of the four thyroid hormones that humans make: T4, T3, T2, T1. The synthetic thyroid replacement, Synthroid/levothyroxine is only T4.  The active form of thyroid is T3, and it requires an enzyme to convert T4 into T3. If a person can't convert T4 into active T3 then nothing improves except the blood levels of T4, and TSH. The majority of women cannot convert T4 into T3. Therefore, if they take Synthroid or levothyroxine and their doctor only checks their TSH level and not the level of free T3 and free T4 to see if the Thyroid is working, then women are told that they are healed, yet they know they are not because none of their low thyroid symptoms are resolved. When this happens, doctors tell female patients that it is all in their heads and dismiss us when we tell them we are not cured with this synthetic T4 medication. Yet Synthroid is a chemical, and AT is natural from medical pigs, so the FDA is trying to Bann the only drug that has successfully treated millions of women. PS. Synthroid was not tested on women like many other drugs that were passed through the FDA before 2014! If you think this is a small problem, think again. Thyroid hormones are vital to human life, and the thyroid gland requires Iodine in the diet. The Midwest US has no Iodine in the soil or water. Therefore, this area is overburdened with hypothyroidism. I have been on AT for 50 years without complication and I have prescribed it thousands of times ever since I went into private practice.  AT works to relieve the symptoms of hypothyroidism for women and men, and it works better for women that the “new” drug Synthroid/levothyroxine, which is FDA approved. You ask how could the FDA approve a drug that doesn't successfully treat women? It is because Synthroid was not tested on women!  Until 2014 the FDA did not test women in the required drug trials.  AT works for us (women), Levothyroxine does not. Now the FDA wants to ban AT. It is not approved because it was around for decades before they started testing medications like they do now, and the history of successful treatment should stand on its own merit! Example 2: Bio-Identical Hormones BIH:  BIHs had not been approved by the FDA until recently and there was no announcement that they are now approved for women who have hormone deficiency symptoms or postmenopausal symptoms. Most doctors and women who have been afraid of the only hormones that can help them, bioidentical hormones, haven't yet been told that NOW, FINALLY the medical colleges and the FDA finally have quietly approved BI hormones.  There are no pure estradiol and pure testosterone pellets that are made by a drug company for women. My patients get their estradiol and testosterone pellets from a compounding pharmacy.  I have been prescribing BIH since 1985 without FDA approval because the oral estrogen formulations that were available at pharmacies caused weight gain and put women at high risk for blood clots. Non-oral BI hormones have fewer risks than FDA approved estrogens.  I waited more than 45 years for the FDA to approve BI hormones for treatment of women.  All those women in the last 45 years who were taking FDA approved estradiol and those who couldn't tolerate them have been harmed by FDA goals of never approving compounded or bio-identical hormones.  The delay has harmed 50% of American women. Example #3 Devices for Weight Loss I was involved in the discovery and testing of a unique device that stimulated acupuncture points with a TENS-unit-type patch connected to your cell phone for easy adjustment of your hunger or “fullness”. The FDA requires testing to approve any new device so the group of investors I was part of had to invest thousands of dollars for a device we already knew worked. The FDA told the investigators of all new devices who they should test, who they can't have in the study, and how long the testing should take. I found their parameters for the study of this device to be unrealistic. The women in our test group could not be taking hormones of any kind (birth control, ERT, HRT), and could not be on antidepressants, could not have diabetes or insulin resistance or be on any drug that assisted in weight loss. These women subjects had to be a certain BMI (level of obesity) and had to be tested repeatedly with weight and body composition measurements None of my patients who needed weight loss could participate.  Most GYN patients are on some medication or supplement, so the FDA made this study of our device so narrow that REAL WOMEN weren't tested! Sadly, we lost many women in the control group from the study because they were NOT losing weight while the ones on the device were obviously dropping pounds, so we had trouble maintaining test subjects. The testing phase of this simple device took 7 years! Our device works and no one will ever know about it or be able to use this non-medicinal weight loss device because when the FDA rejects your device you will be breaking the law if you produce and sell it directly to the public. It has no side effects or dangers..it just controls the amount you eat with stimulation of an acupuncture point. There are many ways to change this situation, and it takes years and billions of dollars to change the whole system of bringing treatments to patients quickly.  I'm afraid I won't see a revolution of the way we bring medicines and devices to market during my lifetime. Currently there is a 17-year delay between proving a drug or device works for a particular illness or condition and when it becomes available to doctors and patients. So what do we do in the meantime?  I seek treatments for patients who are unresponsive to traditional medicine by reading journals like Life Extension, that inform doctors and patients alike about new effective solutions for common medical complaints and diseases that the FDA has ignored or stymied with endless drug trials.  Life Extension Magazine highlights studies on new medications for diseases without an FDA approved solution and publicizes diagnostic tests often overlooked by mainstream publications because they are not yet FDA approved. The medical journals I read (New England Journal of Medicine, JAMA, Menopause, Metabolism and Endocrinology, Journal of Age management, to name a few) offer treatments for orphan diseases or even common problems that haven't been blessed by the FDA. It takes an average of 17 years from the culmination of research on a new drug, test or device until it is approved for use by the public! At the end of this Blog, I will give you a link to make your voice heard by signing a petition to shorten the approval of new treatments and medications from the average of 17 years to 3 years! My patients don't have time to wait for relief, and that may be the case for you as well. If you want to do something to help, please click this link and let the FDA know how you feel. Please sign a Petition to enact an amendment to the FOOD, DRUG and COSMETIC ACT, by going to: https://age-reversal.net/fda/

¡Vótame en los Premios iVoox 2025! Esportmaníacos 2394: En el programa de hoy hemos hablado del primer día del Suizo de Worlds. Europa empieza 0-3, lo cuál lleva a una repetición de la final de la LEC en segunda ronda del Suizo. El primer China contra Corea se lo llevaron los Pandas y 100T dio la sorpresa contra el campeón de la LPL, Bilibili Gaming. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:07:00 - Jordi baneado (y seguimos con la intro) 00:19:25 - El horario de mañana 00:32:00 - Europa peor región del Día 1 00:40:00 - Ostras contra Fnatic 01:00:00 - KOI vs KT 01:15:10 - Drama en Twitter con Cardonetti y Mauro Garih 01:28:20 - 100T vs BLG 01:36:35 - T1 vs FLY 01:40:50 - Primer LPL vs LCK de Worlds 01:47:30 - TES vs G2

⏱ Prvních 21 minut pro všechny zdarma, celý rozhovor v délce 40 minut pro předplatitele na Patreonu 

¡Vótame en los Premios iVoox 2025! Esportmaníacos 2393: ¡Hoy ha empezado Worlds! En el programa de hoy hemos hablado largo y tendido sobre los enfrentamientos que tendremos en la primera fase del Suizo, los enfrentamientos de los equipos europeos y del T1 vs Invictus Gaming que ha decidido quién clasifica al Suizo y quién se queda fuera hasta el año que viene. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g

Na série de conversas descontraídas com cientistas, chegou a vez da Professora Associada do Instituto Tecnológico da Aeronáutica (ITA), Mestra em Física Aplicada e Doutora PhD em Materiais Eletrônicos, Inventora e Ativista, Sonia Guimarães.Só vem!>> OUÇA (86min 14s)*Naruhodo! é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.Edição: Reginaldo Cursino.http://naruhodo.b9.com.br*Sonia Guimarães possui graduação em Licenciatura Ciências - Duração Plena pela Universidade Federal de São Carlos, mestrado em Física Aplicada pelo Instituto de Física e Química de São Carlos - Universidade de São Paulo e doutorado (PhD) em Materiais Eletrônicos - The University Of Manchester Institute Of Science And Technology.Atualmente é Professora Associada I do Instituto Tecnológico da Aeronáutica ITA do Departamento de Ciência e Tecnologia Aeroespacial DCTA.Experiência de pesquisa na área de Física Aplicada, com ênfase em Propriedade Eletroóticas de Ligas Semicondutoras Crescidas Epitaxialmente, atuou principalmente nos seguintes temas: crescimento epitaxial de camadas de telureto de chumbo e antimoneto de índio por difusão, processamento, obtenção e caracterização de dispositivos fotocondutores e sensores de radiação infravermelha.Professora de Física Experimental do 1o e 2o anos das engenharias: elétrica, computação, estruturas de aeroportos, mecânica de aviões, aeronáutica e aeroespacial.Tem experiência na área de Ensino de Física aplicando a Metodologia de Aprendizagem Baseada em Problemas/Projetos ABP (PBL em inglês), utilizando as ferramentas computacionais: Tracker, Arduino e Mathematica. E de Ensino de Física Experimental para Engenheiros, com ênfase em ensiná-los a escrever artigos científicos.Palestrante nos temas: incentivo às meninas para optarem por ciências exatas, tecnologias e engenharias em suas carreiras, revolução digital e as profissões do futuro, empreendedorismo, acolhimento, autoconhecimento e foco para alcançar nossos objetivos e realizar nossos sonhos.Luta contra o racismo e discriminação de gênero, e palestras motivacionais para quem está sendo vítima destes crimes.Membra da Associação Brasileira de Pesquisadores Negros - ABPN, Presidenta da Comissão de Justiça, Equidade, Diversidade e Inclusão - JEDI da Sociedade Brasileira de Física - SBF, Conselheira Fundadora da AFROBRAS, ONG mantenedora da Universidade Zumbi dos Palmares, Conselheira do Conselho Municipal Para a Promoção de Igualdade Racial - COMPIR, da prefeitura da cidade de São José dos Campos, Conselheira Editorial da Revista Ensino Superior.T1. PEDIDO DE PATENTE deferido, e CARTA DE PATENTE registrada, portanto além de cientista agora é inventora de técnica de produção sensores de radiação infravermelha.Está na lista das 100 Pessoas Inovadoras da América Latina de 2023, criada pela Bloomberg Línea. Em 2025 se tornou uma das 15 Mulheres mais Poderosas do Brasil, pela revista FORBES.Lattes: http://lattes.cnpq.br/3737671551535600*APOIE O NARUHODO!O Altay e eu temos duas mensagens pra você.A primeira é: muito, muito obrigado pela sua audiência. Sem ela, o Naruhodo sequer teria sentido de existir. Você nos ajuda demais não só quando ouve, mas também quando espalha episódios para familiares, amigos - e, por que não?, inimigos.A segunda mensagem é: existe uma outra forma de apoiar o Naruhodo, a ciência e o pensamento científico - apoiando financeiramente o nosso projeto de podcast semanal independente, que só descansa no recesso do fim de ano.Manter o Naruhodo tem custos e despesas: servidores, domínio, pesquisa, produção, edição, atendimento, tempo... Enfim, muitas coisas para cobrir - e, algumas delas, em dólar.A gente sabe que nem todo mundo pode apoiar financeiramente. E tá tudo bem. Tente mandar um episódio para alguém que você conhece e acha que vai gostar.A gente sabe que alguns podem, mas não mensalmente. E tá tudo bem também. Você pode apoiar quando puder e cancelar quando quiser. O apoio mínimo é de 15 reais e pode ser feito pela plataforma ORELO ou pela plataforma APOIA-SE. Para quem está fora do Brasil, temos até a plataforma PATREON.É isso, gente. Estamos enfrentando um momento importante e você pode ajudar a combater o negacionismo e manter a chama da ciência acesa. Então, fica aqui o nosso convite: apóie o Naruhodo como puder.bit.ly/naruhodo-no-orelo

Timestamps0:00 Intro4:11 What is the LCK power ranking right now?14:21 Best players in LCK (all-pro discussion)19:56 KT Rolster38:30 T1 (if they make it)1:00:41 HLE1:27:00 GenG1:49:00 Will an LCK team win Worlds

Today we have a packed episode of The Dive Driven by Kia, starting with our 6th Divey Awards! Kobe, Azael and Meteos discuss the ongoing Promotion Tournament and the competitive ruling in the match between Disguised and Estral Esports. We also break down Patch 25.20 and look ahead to Worlds starting next Tuesday with an iconic showdown between reigning world champions T1 and their LPL rivals, Invictus Gaming. Faker, Rookie, TheShy… ever heard of em? But wait, there's moore. Stick around to the end of the show for an interview with Rob Moore, CEO of the newest team joining the LCS next year: Sentinels. Any SEN City fans in the chat?Put your Worlds Pick'Ems up against other fans of The Dive here: https://lolesports.com/en-US/pickems/113475452383887518/leaderboards/3583099272971478637?id=373339142607088131Timestamps:00:00:00 - Intro00:00:52 - Pro Most Deserving of an Award Award00:01:28 - Best Champion of the Split Award00:02:43 - Please Don't Leave Us Award00:03:45 - Strongest Laner00:05:16 - Best Game of the Split Award00:06:48 - Best Coach/Player00:08:03 - Best Social Media Presence00:09:56 - The Best Celebration Award00:10:56 - The Atakhan Award00:13:18 - The Chime Minister (Best Bard NA)00:14:30 - The Hardest Carry Award00:15:38 - Tried so hard but in the end it doesn't even matter00:16:34 - Biggest Fumble00:18:07 - I'm Still Scaling Award00:19:18 - Promotion Tournament00:27:03 - Worlds Patch 25.2000:45:09 - Worlds LCK Preview01:09:16 - Worlds LPL Preview01:26:30 - Worlds LEC Preview01:38:57 - Worlds LCP Preview01:50:39 - Back from the break! Interview with Sentinels CEO Rob

Send us a textWe sit down with Jen Forick, nurse practitioner and co-owner of CrossFit T1, to explore how coaching, caregiving, and community can build lasting health. From palliative care lessons to snatch Sundays and Wellness Wednesday, this is about turning a gym into a true wellness engine.• what palliative care really is and how it shapes Jen's view of quality of life• using workouts as an emotional reset and resilience builder• the path from commercial gyms to barbell proficiency and gymnastics capacity• simple nutrition rules: walk more and eat enough protein• EMOMs for fundamentals: chest-to-bar, toes-to-bar, and smart progressions• lessons from ownership: respond slowly, be visible, earn trust• building T1 as a one-stop wellness hub: nutrition, PT, and responsible hormone literacy• community churn, returns, and keeping the culture strong• watching CrossFit HQ's next chapter and what it could mean for affiliates• longevity over aesthetics: training that pays dividends in everyday lifePlease like and subscribe to the show on all streaming platforms

Dr. Monty Pal and Dr. Matteo Lambertini discuss a compelling global study on the clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, the association of pre-diagnostic awareness of BRCA status with prognosis, and the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants. TRANSCRIPT Dr. Monty Pal: Well, hello everyone, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. Now, when we think about genetic testing, whether for patients diagnosed with breast cancer or for other family members of them, it seems to be widely underutilized. Today, we're going to be discussing a recently published study in the Journal of Clinical Oncology that reported on the clinical behavior of breast cancer and specifically young BRCA1 and BRCA2 carriers, and the association of pre-diagnostic awareness of BRCA status with prognosis. I thought this was just a fascinating piece, and I honestly couldn't wait to have this conversation. It's a really compelling paper that highlights the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants, and really the need for genetic counseling and testing to inform people about early detection that could lead to a better prognosis. I'm really delighted to welcome the study's lead author, Dr. Matteo Lambertini. He really needs no introduction. He's very well known in the breast cancer world for his amazing contributions to fertility in the context of breast cancer, to pregnancy in the context of breast cancer, and genetic testing. He's an associate professor at the University of Genova, and a breast cancer medical oncologist at the San Martino Polyclinic Hospital in Genova, Italy.  Dr. Lambertini, thank you so much for joining us today. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a great pleasure. Dr. Monty Pal: Oh, thanks. And just FYI, if you're listening in and you want to hear our disclosures, they're all listed at the transcript of this podcast.  So, I poured through this paper [Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status] yesterday, Dr. Lambertini, and first of all, congratulations on this study. This was a huge international multicenter effort, 4,752 patients. How did you pool all these patients with young breast cancer? Dr. Matteo Lambertini: Thanks a lot for the question. Yes, this was an effort made by several centers all over the world. The main idea behind the creation of this network that we have named as BRCA BCY Collaboration, was to get as many data as possible in a sort of niche patient population in the breast cancer field, meaning women diagnosed with breast cancer at the age of 40 years or younger, and all of them being BRCA carriers. We know that around, in the Western world, around 5% of breast cancer cases are being diagnosed under the age of 40 years, and among them around 10-15% are BRCA carriers. So, I would say it's a relatively rare patient population where we did not have a lot of evidence to support our choices in terms of counseling on treatment, prevention, and oncofertility as well. That was the idea behind the creation of this network that includes many centers. Dr. Monty Pal: Yeah. You know, what's so interesting about this is that you sort of draw this line between patients who have BRCA testing at the time of diagnosis and then BRCA testing earlier in their course and then leading to a diagnosis perhaps. And I think that's where really sort of the dichotomy in outcome sits. Can you maybe elaborate on this and tell us about timing of genetic testing in this study and what that meant ultimately in terms of prognosis? Dr. Matteo Lambertini: In this specific analysis from this large network, including almost 5,000 women with breast cancer diagnosed at the age of 40 years or younger and being a BRCA carrier, we looked specifically into the timing of genetic testing because this is a retrospective study and the criteria for inclusion are those that I have just mentioned, so diagnosis at a young age plus carrying germline BRCA pathogenic or likely pathogenic variant. In this analysis, we have looked into the time the patient has got the genetic testing and particular we focused on two populations: those that were diagnosed, knowing already to be a BRCA carrier, and those that got tested after being diagnosed with breast cancer. And the main findings from this analysis have been that knowing to be a BRCA carrier was associated with a lower stage at the time of diagnosis, meaning more T1 tumors, so a tumor less than 2 cm, more node-negative disease, and this translated into less aggressive treatment, so less often axillary dissection, less often use of chemotherapy and anthracycline-based chemotherapy. And even more importantly, we have seen a better overall survival for those patients that were diagnosed already knowing to be BRCA carriers as compared to those tested after breast cancer diagnosis. These results after adjusting for all the confounding, stage, treatment and so on, there was not significant anymore, meaning that it's not the timing of test per se that is probably leading to a better survival, but it is the fact that knowing to be a BRCA carrier would likely translate into having access to all the preventive measures that we have in this setting and this will translate into an overall survival benefit, so in terms of saving more lives in young BRCA carriers. Dr. Monty Pal: I think it's such an important point, and it's one that I think might sound implicit, right, but it needs to be proven, I think, through a study like this. You know, the fact that finding this early, identifying the mutation, doing enhanced screening, and so forth, is really going to lead to superior clinical outcomes. One of the things that I think many people puzzle over, including myself, is what to do? I personally occasionally will see BRCA altered patients in the context of prostate cancer. But that's a very different population of individuals, right? Typically older men. In young females with BRCA mutation, I guess there's a specific set of considerations around reproductive health. You'd already highlighted preventive strategies, but what sorts of things should we be talking about in the clinics once a patient's diagnosed and once perhaps their breast cancer diagnosis is established? Dr. Matteo Lambertini: Yes, exactly. Knowing to be a BRCA carrier has a lot of implications from prevention to treatment to survivorship issues including reproductive counseling. And this is important not only for the patient that has been diagnosed with breast cancer but also for all the family members that will get tested and maybe identify with this sort of genetic alteration before diagnosis of cancer. Why this is important is because we have access to very effective preventive measures, a few examples: MRI screening, which starts at a very young age and normally young women don't have an effective screening strategy outside the BRCA field. Also, primary preventive measures, for example, risk-reducing surgery. These women are known to have a high risk of breast cancer and high risk of ovarian cancer. So the guidelines are suggesting to undergo risk-reducing salpingo-oophorectomy at a young age, so 35 to 40 years in BRCA1 carrier, 40 to 45 years in BRCA2 carrier. And also risk-reducing mastectomy should be discussed because it is a very effective way to prevent the occurrence of breast cancer. And in some situations, including the setting that we are talking about, so young women with breast cancer, BRCA carrier, also risk-reducing mastectomy has shown to improve overall survival.  On the other side, once diagnosed with breast cancer, nowadays knowing to be or not a BRCA carrier can make a difference in terms of treatment. We have PARP inhibitors in the early setting, in the adjuvant setting as well as in the metastatic setting. And in terms of survivorship implication, one of the critical aspects for young women is the oncofertility care which is even more complicated when we talk about BRCA carriers that are women candidates for gynecological surgery at a very young age. So this sort of counseling is even more complicated. Dr. Monty Pal: One of the other things, and this is subtle in your paper and I hope you don't mind me bringing it up, is the difference between BRCA1 and BRCA2. It really got me thinking about that because there are differences in phenotype and manifestation. Do you mind just expanding on that a little bit for the audience because I think that's a really important reminder that you brought up in the discussion? Dr. Matteo Lambertini: The difference between BRCA1 and BRCA2 carriers has been known that there are different phenotypes of breast cancer that are more often diagnosed in these two different populations. Normally BRCA1 carriers have a higher likelihood to develop a triple negative breast cancer as compared to BRCA2 carriers, more likely to develop a hormone receptor-positive HER2-negative disease. In this study, again, a specific population of young women with breast cancer, we have seen the same findings, mostly triple negative disease in BRCA1 carrier, mostly luminal-like disease in BRCA2 carrier. But what's novel or interesting from this study is to look also at the age at the time of diagnosis of this disease. And particularly in BRCA1 carriers, we should be sort of more careful about diagnosis of breast cancer and also other primary tumors including ovarian cancer because the risk of developing these malignancies is higher even at a younger age as compared to BRCA2 carriers. And this has implications also in the primary and secondary prevention that we were talking about earlier. Dr. Monty Pal: Oh, interesting. I guess the fundamental question then from your paper becomes, how do we get at the right patients for screening for BRCA1 and BRCA2? And I realize our audience here is largely oncologists who are going to be listening to this podcast, oncology providers, MDs, nurses, etc. But maybe speak for a moment to the general practitioner. Are there things that, for instance, a general practitioner should be looking for to say, “Wait a minute, this patient's high risk, we should consider BRCA1, BRCA2 testing or germline screening”? Dr. Matteo Lambertini: Yes, it's a very important question for the breast cancer community. After the updated ASCO guideline, the counseling is way easier because right now the age cutoff goes up to 65 years, meaning that all the patients diagnosed with breast cancer below the age of 65 years should be tested these days. And then above the age of 65, there are different criteria like triple-negative disease or family history. From a general practitioner standpoint, it's of course a bit more difficult, but knowing particularly the family history of the person that they have in front will be crucial to know if there are cases of breast cancer diagnosed at a young age, maybe triple-negative cases, knowing cases of ovarian cancer in first-degree relatives or pancreatic cancer in first-degree relatives, and of course cases of prostate cancer as well. So, I would say probably mostly the family side will be important from a general practitioner perspective.  From an oncology one, the other point that I think is important to stress also based on the data that we have shown in this publication is that having a case of breast cancer known to carry a BRCA pathogenic or likely pathogenic variant. It means that all the people around this case should get tested and if found to be BRCA carrier and healthy carrier, these people should also undergo the primary and secondary prevention strategies because this is very critical also to improve their outcomes and try to avoid the developing of breast or ovarian cancer, but also in the case of diagnosis of this disease, a diagnosis at an earlier stage, as we have seen in this paper. Dr. Monty Pal: Brilliant. I'm going to diverge from our list of questions here and close by asking a question that I have at the top of my mind. You're very young. I know our podcast listeners can't see you, but you're very, very young. Dr. Matteo Lambertini: Thank you. Thank you for that. Not so young but yeah. Dr. Monty Pal: You have nearly 300 papers. Your H-index is 67. You've already made these seminal contributions, as I outlined it from the outset, regarding fertility, regarding use of GnRH analogs, regarding pregnancy and breast cancer. What are you studying now? What are you really excited about right now that you're doing that you think might potentially be practice changing? Give us a little teaser. Dr. Matteo Lambertini: Yeah. Thanks a lot, Dr. Pal. Receiving this compliment from you is fantastic. So, thanks a lot for that. From my side, in terms of my research, I've been interested in the field of breast cancer in young women since the start of my training. I've had very good mentors from Italy, from Europe, from the U.S. I'm still interested in this field, so I think we still have a lot to learn to try to improve the care of young women with breast cancer. For example, the oncofertility care, which is something I worked a lot over the past years. Now with all the new treatment options, there's a sort of new chapter of oncofertility counseling. So, what's the impact of immunotherapy? What's the impact of the new targeted agents?  More on the genetic aspects, now we know that there's not only BRCA1 or BRCA2. There are a lot of other different genes that may increase the risk of breast cancer and other malignancies. And also for these genes, we really don't have a lot of evidence to counsel women on prognosis, treatment, prevention strategy. So we need to learn way more for this special patient population that are quite rare, and so we really need a multicenter academic effort to try to give some evidence in this field. Dr. Monty Pal: Yeah. It's tough because these are rare circumstances, but, you know, I think that you've done really well to sort of define some collective experiences that I think really define therapy. I mean, I just remember when I was in training 25 years ago, just reading through textbooks where all the experience around breast cancer and pregnancy was really just very sort of anecdotal almost, you know? And so it's great to see that the state of the science has moved forward.  Well, gosh, I really enjoyed our conversation today. I think your study really reminds us how powerful genetic information is in terms of improving outcomes. And, you know, hopefully this will lead some individuals to perhaps test more broadly in appropriate settings. So, thank you so much, Matteo, for joining us today with your fantastic insights on the ASCO Daily News Podcast. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a real pleasure. Dr. Monty Pal: And thanks to our listeners too. You'll find a link to Dr. Lambertini's study in the transcript of this episode. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks a ton. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Sumanta (Monty) Pal  @montypal  Dr. Matteo Lambertini @matteolambe   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Monty Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Matteo Lambertini: Consulting or Advisory Role: Roche, Novartis, Lilly, AstraZeneca, Pfizer, MSD, Exact Sciences, Gilead Sciences, Seagen, Menarini, Nordic Pharma Speakers' Bureau: Takeda, Roche, Lilly, Novartis, Pfizer, Sandoz, Ipsen, Knight Therapeutics, Libbs, Daiichi Sankyo, Gilead Sciences, AstraZeneca, Menarini, AstraZeneca, Menarini Research Funding (Inst.): Gilead Sciences Travel, Accommodations, Expenses: Gilead Sciences, Daiichi Sankyo Europe GmbH, Roche

Esportmaníacos 2380: En el programa de hoy hemos tenido mucho, mucho mercato. Hemos traído en exclusiva varios rumores de lo que podría pasar en la offseason y destapado lo importante que va a ser el Fnatic vs Karmine Corp de mañana para el futuro de la LEC. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:18:20 - Top Esports a Worlds, ¿quién irá contra T1? 00:24:40 - Primer rumor de offseason 01:14:03 - Segundo rumor de offseason 01:28:25 - Tercer rumor de offseason 01:47:00 - Darthy habla de las renovaciones en KOI

An overview of Magnetic Resonance Imaging (MRI), beginning from the basic physics of nuclear magnetic resonance, and covering the use of radiowaves to excite nuclear spin states, and the T1 and T2 modes of relaxation. We then explore how these phenomena are used to produce 3d images, including magnetic field gradients, frequency encoding, phase encoding, and Fourier transforms. We conclude with a discussion of functional imaging, including the haemodynamic response, the BOLD signal, echo planar imaging, and the steps of preprocesing. Recommended pre-listening is Episode 14: Principles of Quantum Mechanics, and Episode 61: Magnetism. If you enjoyed the podcast please consider supporting the show by making a PayPal donation or becoming a Patreon supporter. https://www.patreon.com/jamesfodor https://www.paypal.me/ScienceofEverything

PLAT CHAT MERCH IS HERE!! https://platchat.com/ Members check the Discord or Community Posts tab on Youtube for $5 off your purchase

Today's episode is an update on what's happening inside the Puma Project3 in terms of the help we've been getting as well as the first drop of gear including the Fast R3s.I'll go through why I've had to make some changes to my marathon preparation even though Belfast went so well. Sometimes you might be forced into changes but it's also worth looking at what improvements you can make.I round off with a bit of an insight into how I'm trying to manage my T1 diabetes slightly differently given the difficulties I had in my previous races.The master the marathon course will get you ready and confident for your upcoming race by helping you plan your fuel, mindset and pacing. Sign up now at ⁠⁠⁠⁠⁠⁠www.therunningrules.com/master-the-marathon

In this episode of The Tax Chick Podcast, I am joined by my friend and fellow professional, Michelle D. Coleman, to dig into a topic that every executor needs to understand: the tax implications that arise after someone passes away.Michelle shares her expertise on the common questions and pitfalls that executors face when navigating taxes on death. Together, we walk through the fundamentals of estate administration, tax filings, and why early planning and communication are so important.We cover:The different tax returns that may need to be filed (terminal T1 return, estate T3 return, and more).How the deemed disposition of assets works in Canada — and what it means for executors.Why personal property (antiques, jewelry, collections, etc.) can create unexpected tax issues.The importance of holdbacks, communication with beneficiaries, and managing expectations.Special considerations for non-resident beneficiaries and why CRA clearances matter.The often-overlooked rules around executor compensation and tax reporting.Building a collaborative team of advisors (lawyer, accountant, investment professional) to help executors succeed.If you have ever wondered what happens from a tax perspective after someone dies, or if you have been named an executor and feel unsure where to begin, this episode will give you a clear roadmap of what to expect and why it is so important to get the right advice early on.MORE ABOUT OUR SPECIAL GUEST:Michelle Coleman  HERE ARE SOME OTHER WAYS TO CONNECT WITH ME:My website! Email: thetaxchickpodcast@gmail.com@tax.chick (IG) LinkedInBe a "Tax Chick VIP"

Esportmaníacos 2377: En el programa de hoy hemos hablado del enfrentamiento entre KC y FNC y cómo el duelo estilistico puede penalizar a Razork y compañía en el evento de la LEC en Madrid. También hemos hablado largo y tendido de T1, ya clasificado a Worlds pero como Seed 4 de la LCK, por lo que tendrá que jugar en el play-in contra el Seed 4 de la LPL para presentarse en el Suizo. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:12:40 - ¿Por qué hubo una semana de descanso de LEC? 00:15:53 - No sé se nos va la olla 00:20:45 - Gentlemates parece que entrará en VCT 00:23:10 - Info del Game Changers de LoL 00:25:00 - Gen G se impone a T1 00:51:25 - Se retira Peanut 00:58:20 - KC vs FNC 01:22:50 - Trailer de la LEC en Madrid 01:35:10 - Impact deja Team Liquid 01:39:05 - ¿Shadow e Impact mejores que Elyoya, Razork o Yike? 01:50:50 - Echamos de menos el regional en Europa

Esportmaníacois 2375: ¡En el programa de hoy hemos hablado de T1 llegando a Worlds, Dplus KIA yendo al nuevo invitacional asiático y de varios rumores del mercato! Llegado cierto punto se nos va la olla así que disfruten del caos. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:10:00 - Mundial de maulas y desvaríos varios 00:21:20 - T1 a Worlds 00:40:55 - Rumor de Vitality 00:55:45 - Rumor de Heretics 01:32:50 - Own3r mantiene a SK 01:50:00 - Nada tiene sentido

In this episode of Summoning Insight, we dive deep into one of the wildest weeks in competitive League of Legends across LCK, LPL, LEC, and LTA/LCS. If you love in-depth League of Legends esports analysis covering LCK playoffs, League of Legends analysis, T1 vs Gen.G, BLG vs TES, and LEC playoffs — this episode is a must-watch! Visit https://www.Kalshi.com and use promo code LFN. Make your first $100 worth of trades and you'll automatically receive a $10 bonus! Sign up for your $1 per month trial and start selling today at https://shopify.com/summoning  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Assistant Professor Mohammad Mirhosseini (Caltech EE/APh) explains how his group built a mechanical quantum memory that stores microwave-photon quantum states far longer than typical superconducting qubits, and why that matters for hybrid quantum architectures. The discussion covers microwave photons, phonons, optomechanics, coherence versus lifetime (T2 vs. T1), current speed bottlenecks, and implications for quantum transduction and error mechanisms. The discussion centers on a paper from Mirhosseini's paper from December of 2024 titled, “A mechanical quantum memory for microwave photons,” detailing strong coupling between a transmon and a long‑lived nanomechanical oscillator for storage and retrieval of nonclassical states.GuestMohammad Mirhosseini is an Assistant Professor of Electrical Engineering and Applied Physics at Caltech, where his group engineers hybrid superconducting–phononic–photonic systems at millikelvin temperatures for computing, communication, and sensing. He completed his PhD at the University of Rochester's Institute of Optics and was a postdoc in Oscar Painter's group at Caltech before starting his lab. His recent team effort demonstrates mechanical oscillators as compact, long‑lived quantum memories integrated with superconducting circuits.Key topicsWhat “microwave photons” are and how qubits emit/absorb single microwave photons in circuit QED analogously to atoms and optical photons.Why “memory” is missing in today's quantum processors and how a dedicated long‑lived storage element can complement fast but dissipative superconducting qubits.Optomechanics 101: mapping quantum states between electrical and mechanical degrees of freedom, with phonons as the quantized vibrational excitations.T1 vs. T2: demonstrated order‑of‑magnitude gains in lifetime (T1) and more modest current gains in coherence (T2), plus paths to mitigate dephasing.Present bottleneck: state conversion between qubit and oscillator is about 100× slower than native superconducting operations, with clear engineering avenues to speed up.Quantum transduction: leveraging the same mechanical intermediary to bridge microwave and optical domains for interconnects and networking.Two‑level system (TLS) defects: shared decoherence mechanisms across mechanical oscillators and superconducting circuits and why comparing both can illuminate materials limits.Why it mattersHybrid architectures that pair fast processors with long‑lived memories are a natural route to scaling, and mechanical oscillators offer lifetimes far exceeding conventional superconducting storage elements while remaining chip‑integrable.. Demonstrating nonclassical state storage and retrieval with strong qubit–mechanics coupling validates mechanical oscillators as practical quantum memories and sets the stage for on‑chip transduction. Overcoming current speed limits and dephasing would lower the overhead for synchronization, buffering, and possibly future fault‑tolerant protocols in superconducting platforms.Episode highlightsA clear explanation of microwave photons and how circuit QED lets qubits create and absorb them one by one.Mechanical memory concept: store quantum states as phonons in a gigahertz‑frequency nanomechanical oscillator and read them back later.Performance today: roughly 10–30× longer T1 than typical superconducting qubits with current T2 gains of a few×, alongside concrete strategies to extend T2.Speed trade‑off: present qubit–mechanics state transfer is ~100× slower than native superconducting gates, but device design and coupling improvements are underway.Roadmap: tighter coupling for in‑oscillator gates, microwave‑to‑optical conversion via the same mechanics, and probing TLS defects to inform both mechanical and superconducting coherence.

Welcome to a new episode of Power Spike! This week, we discuss the LTA Playoffs and the status of LoL esports teams like FlyQuest, Cloud9, 100 Thieves, and Shopify Rebellion, T1's narrow victory over Dplus in the LCK Playoffs, League of Legends champion picks in the meta, the LPL Playoffs, and more! 

In this episode of Summoning Insight, Thorin and Yamato break down another intense week of League of Legends esports action, covering everything from the LPL and LCK playoffs to the heated drama surrounding Bwipo and FlyQuest. The duo dives deep into FlyQuest's dominant run, Bwipo's controversial comments, and the ripple effects across the LoL competitive scene. They also analyze standout performances, strategic drafting in the Fearless format, and the challenges teams face ahead of Worlds 2025. Expect sharp insights, bold takes, and plenty of debate about player reputations, team culture, and how mental resilience shapes championship runs. Beyond the Bwipo controversy, the show dissects key playoff series across major regions, including T1's shaky showing in the LCK, the rise of underdog teams in the LPL, and high-stakes matchups in the LEC featuring KOI, Fnatic, and Karmine Corp. With expert commentary grounded in years of esports experience, Summoning Insight delivers the context and storytelling that fans of LoL crave. Whether you're here for the strategy talk, the inside scoops, or the drama that shakes the pro scene, this episode connects you to the heart of competitive League of Legends. If you're looking for unfiltered insights, bold predictions, and in-depth playoff previews, this is an episode you won't want to miss! Protect your online privacy TODAY by visiting https://ExpressVPN.com/summoning and you can get up to four extra months FREE. Upgrade your wallet today! Get 10% Off Ridge with code SI at https://www.Ridge.com/SI Get up to 10 FREE meals and a free item for life at https://www.hellofresh.com/lfn10fm Go to https://www.buyraycon.com/LFN TODAY to get up to 20% off sitewide!

In the second episode from race week in Nice, host Matt Lieto connects with another trio of top contenders for the IRONMAN World Championship title: Sam Laidlow, Marten van Riel, and Matthew Matthew MarquardtFirst, defending Nice champion Sam Laidlow reflects on a challenging year that started with a reactivation of the Epstein-Barr virus. He explains how the forced rest shifted his perspective from chasing numbers to focusing on quality, health, and a more holistic preparation. This new approach led to breakthrough performances on surprisingly low training volume, giving him a newfound "inner peace and confidence" as he looks to defend his title on French soil.Next, Marten van Riel opens up about his turbulent and "panicky" build-up to his first full-distance World Championship, which included a significant ankle injury that limited him to a four-week run block and a minor crash on the course just days before the race. Despite the setbacks, the Belgian Olympian discusses the freedom that comes from lowered expectations and his excitement to race on a course he feels is perfectly suited to his strengths.Finally, American Matthew Marquardt details his season of two halves, from frustrating early-season results to dominant victories at IRONMAN Cairns and Lake Placid. The medical student gives a fascinating deep-dive into the physiological cause of the quad spasms that have affected him in T1 and explains the strategic evolution in his racing—learning to conserve energy on the bike to unleash his now formidable run, which he believes is the key to competing with the best in the world.

Transitions can make or break your race, and Transition 1 is often where valuable seconds slip away. In this episode, we take a deep dive into the ins and outs of T1 with Coaches Jeff Raines and Jenn Reinhart. From sighting the swim exit and navigating the chaos of the transition area, to smart gear staging and finding your bike fast, they share practical tips and real-world strategies to streamline your next race. Plus, enjoy some unforgettable stories from their own triathlon journeys. Whether you're a first-timer or a seasoned racer, this episode will help you move from swim to bike like a pro.

Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

In this episode of Summoning Insight, Thorin and Yamato dive deep into the state of League of Legends across multiple regions, starting with the chaos surrounding the LEC Playoffs. They tackle Riot's scheduling controversies, format missteps, and break weeks, then break down the strengths and weaknesses of top contenders like G2, Fnatic, Karmine Corp, and KOI. Expect sharp takes on G2's perfect split, Fnatic's month-long break before playoffs, KC's internal drama, and whether KOI can mount another title or a LoL Worlds 2025 run. The conversation then moves globally, with heated analysis of the LCK Playoffs picture and GenG's historically dominant regular season, plus whether T1 can challenge them. In LTA North, the hosts unpack 100 Thieves' surprise takedown of Team Liquid, Cloud9's shaky form against lower-tier teams, and the looming dominance of FlyQuest. The episode also previews the high-stakes LPL playoffs and features candid opinions on player form, team building, and what it takes to perform on stage in the most competitive LoL esports environments. If you're looking for unfiltered insights, bold predictions, and in-depth playoff previews, this is an episode you won't want to miss!Visit https://prizepicks.onelink.me/LME0/SUMMONING and use code SUMMONING and get $50 in lineups when you play your first $5 lineup! Last Free Nation's new collaboration t-shirt with Into the AM is out now! Equip yourself with this high-quality shirt (featuring a familiar insignia) now! While you're there, you can also shop the Into the AM Labor Day Sale! Items are up to 50% sitewide until the 7th of September. This is in addition to the 10% off you always get by using our link: https://intotheam.com/LFN-tee2 Go to https://www.buyraycon.com/LFN TODAY to get up to 20% off sitewide! Control Body Odor ANYWHERE with Mando and get 20% off + free shipping with promo code SUMMONING at shopmando.com!

First Pick   Ultimate Guard Roundup Statement on Generative AI: https://bsky.app/profile/ultimateguard.bsky.social/post/3lwwcrte4l22b Harry Potter Boxes Removed: https://cdn.discordapp.com/attachments/410942703623208960/1408125065328984164/Screenshot_2025-08-21_at_17.25.23.png?ex=68b08329&is=68af31a9&hm=13ac080905333d58e4a63819c0f680ed72f072b02b952d2699169dd94b9750cf& Rhystic Studies Resigns: https://cdn.discordapp.com/attachments/410942703623208960/1410272968906637413/Screenshot_20250827-101320.png?ex=68b06a8d&is=68af190d&hm=fe3cf0ef64a5274a094c18de8b24dd294ff8a9c24f35b7a3330338be649d2db5& https://bsky.app/profile/rhysticstudies.bsky.social/post/3lxf7g2rbl22y   Gather the Townsfolk   EDHREC's Survey: https://bsky.app/profile/edhrec.com/post/3lxajold4o626 https://bsky.app/profile/veggiewagon.bsky.social/post/3lxbed5qf6c2m   Desperate Ravings   Vivi Cauldron Dominates NRG Series: https://bsky.app/profile/emmapartlow.com/post/3lx3tcja6y22i Timing of Next Scheduled B&R Announcement: https://bsky.app/profile/themaverickgirl.bsky.social/post/3lxbdtwjg2224   Maro Talks UB (Again (Again (Again))): https://markrosewater.tumblr.com/post/792626213105647616/i-feel-like-its-a-little-disingenuous-to-continue   Splash Damage   Hareruya Suspends Shipping to US: https://bsky.app/profile/fireshoes.bsky.social/post/3lxcoprcrd22c   The Finisher   The 2025 ESports Awards presented by T1 happened last week, and they included awards for the last decade. Some of the honors went to player of the decade Faker, on-air talent of the decade Sjokz (“shocks”), and game of the decade League of Legends. Now, obviously T1 is a LoL company, so tell me: if you were giving an award in gaming for the last decade who would you like to see honored?

This week on Summoning Insight, we're tackling the big talking points in the world of League of Legends esports! First, we dive into the latest Esports Awards: was Faker the only choice for Player of the Decade? We debate the winners and the merits of the selection process. Then, we dissect the turbulent LCK! What's going on with T1? Can GenG be stopped? We break down KT's SHOCKING victory over T1 and what it means for both teams, T1's recent struggles and their crucial upcoming matches, and Gen G's DOMINANCE: their secret sauce, adaptable playstyle, and individual player brilliance (Chovy & Ruler!). We go BEHIND THE SCENES and explore the vital role of COACHING in esports. Learn about the challenges of managing star players, building trust, and creating a winning team environment. Yamato shares personal experiences and insights from his own coaching career. Don't miss out on this packed episode, including analysis from the latest matches from LTA and LPL! Tune in to get your Summoning Insight fix! Sign up for your $1 per month trial and start selling today at https://shopify.com/summoning Shop the Into the AM Labor Day Sale! Items are up to 50% sitewide until the 7th of September. This is in addition to the 10% off you always get by using our link: https://intotheam.com/lfn Eat smart with Factor! Go to https://FactorMeals.com/lfn50off and use code lfn50off to get 50% off your first box, plus Free Breakfast for 1 Year.

Thorin and Yamato discuss the state of T1 compared to LCK rival GenG, where Fnatic stands in the LEC, Shopify Rebellion's massive upset over Cloud9 in the LTA, IG's thrilling surprise victory over BLG in the LPL, and more! Go to https://www.buyraycon.com/lfn TODAY to get up to 20% off the fan-favorite Everyday Earbuds Classic! Control Body Odor ANYWHERE with Mando and get 20% off + free shipping with promo code SUMMONING at shopmando.com!